Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Celldex Therapeutics (CLDX) Return on Capital Employed (2016 - 2025)

Celldex Therapeutics (CLDX) has 15 years of Return on Capital Employed data on record, last reported at 0.51% in Q4 2025.

  • For Q4 2025, Return on Capital Employed fell 25.0% year-over-year to 0.51%; the TTM value through Dec 2025 reached 0.51%, down 25.0%, while the annual FY2025 figure was 0.45%, 12.0% down from the prior year.
  • Return on Capital Employed reached 0.51% in Q4 2025 per CLDX's latest filing, down from 0.41% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.03% in Q4 2021 and bottomed at 0.51% in Q3 2023.
  • Average Return on Capital Employed over 5 years is 0.29%, with a median of 0.31% recorded in 2025.
  • Peak YoY movement for Return on Capital Employed: tumbled -38bps in 2023, then grew 28bps in 2024.
  • A 5-year view of Return on Capital Employed shows it stood at 0.03% in 2021, then plummeted by -888bps to 0.34% in 2022, then crashed by -34bps to 0.45% in 2023, then skyrocketed by 44bps to 0.25% in 2024, then crashed by -100bps to 0.51% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Capital Employed were 0.51% in Q4 2025, 0.41% in Q3 2025, and 0.34% in Q2 2025.